Refractory follicular B-cell non-Hodgkin’s lymphoma

The PBS subsidises idelalisib for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.

Treatment with idelalisib can be subsidised through the PBS under section 85 of the National Health Act 1953 for patients with refractory follicular B-cell non-Hodgkin’s lymphoma.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing idelalisib.

Applications

Initial treatment

Make all applications for initial authority approval to prescribe idelalisib for the treatment of follicular B-cell non-Hodgkin’s lymphoma in writing and:

All applications for idelalisib must include a completed:

Continuing treatment

Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

Page last updated: 1 October 2017